CCOA Therapeutics Has Launched a COVID-19

Response Program

Toronto, March 16, 2020

CCOA Biotechnology at CCOA Therapeutics has launched a new program for the prevention and treatment of COVID-19, including development and production of preventative agents against COVID-19; production of recombinant SARS-CoV-2 spike glycoprotein and recombinant angiotensin-converting enzyme 2 protein; developing novel anti-SARS-CoV-2 drugs including monoclonal antibody and aptamer drugs; establishing a new anti-SARS-CoV-2 antibody detection kit; design and manufacture novel medical devices to purify neutralizing antibodies from COVID-19 patients in the recovery phase.